Consun Pharma

Consun Pharma, a Pharmaceutical Preparation Manufacturing company headquartered in China, has reported its carbon emissions, though specific total emissions data for 2023 is not available.

For 2022, Consun Pharma reported total Scope 1 and Scope 2 emissions of approximately 72,057,200 kg CO2e. This included Scope 1 emissions of around 53,214,680 kg CO2e and Scope 2 emissions of about 18,842,520 kg CO2e.

Looking back, in 2021, the company's total Scope 1 and Scope 2 emissions were approximately 71,151,211.4 kg CO2e, comprising roughly 52,549,121.4 kg CO2e from Scope 1 and 18,602,090 kg CO2e from Scope 2. In 2020, total Scope 1 and Scope 2 emissions were around 31,857,680 kg CO2e (Scope 1: approximately 16,418,910 kg CO2e; Scope 2: approximately 15,438,760 kg CO2e). For 2019, combined Scope 1 and 2 emissions were approximately 28,163,260 kg CO2e, with Scope 1 emissions around 15,470,130 kg CO2e and Scope 2 emissions about 12,693,130 kg CO2e. In 2017, the company reported total Scope 1 and Scope 2 emissions of approximately 21,049,000 kg CO2e.

Consun Pharma has committed to reducing its absolute Scope 1 and Scope 2 emissions by at least 42% by 2030, using 2021 as the base year. This target is cascaded from Asker. The company currently does not disclose Scope 3 emissions.